Clinical Trial Update: Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034） [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial updating on Anlotinib combined with Docetaxel for advanced non-small cell lung cancer (ALTER-L034).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: The Affiliated Hospital of Qingdao University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN